alexa Toxic Erythema Of Chemotherapy: A Single Center Retrospective Review
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

14th International Conference on Clinical and Experimental Dermatology
June 19-20, 2017 Philadelphia, USA

Alvaro J Rodriguez, Manrup K Hunjan, Lauren Bonomo, Alina G Bridges, Shahrukh K Hashmi and Rokea El-Azhary
Icahn School of Medicine at Mount Sinai, USA
Mayo Clinic, USA
Posters & Accepted Abstracts: J Clin Exp Dermatol Res
DOI: 10.4172/2155-9554-C1-060
Abstract
Background: Toxic erythema of chemotherapy (TEC) is a relatively new term used to describe a spectrum of clinical cutaneous entities that occur after initiation of cytotoxic chemotherapeutic agents such as antimetabolites (i.e. cytarabine) and anthracyclines (i.e. doxorubicin). Typically, it presents as a severe skin reaction manifesting as acral erythema, edema and dysesthesias of the hands and feet. The goal of this study is to more clearly define various clinical and histological presentations of TEC and identify the most common causative agents. Methods: We retrospectively reviewed the charts of 500 patients who had undergone allogeneic or pe-ripheral stem cell transplant from January 2010 to December 2015 and were receiving chemotherapy. Out of 500 patients, only 39 had cutaneous manifes-tations consistent with TEC. Each patient’s skin bi-opsy was reviewed with a dermatopathologist to con-firm features of TEC. Data extracted included age, gender, distribution and morphology of rash, chemo-therapy used, timing and resolution of drug reaction, underlying malignancy and histopathological fea-tures. Results: The incidence of TEC in our cohort was 7.8% with the majority of cases occurring in patient with acute myeloid leukemia (41%). Out of the 39 cases, 24 were males (61%) and 15 were females (39%); the mean age of the patients was 44.1 years. Mean time to onset of the rash from administration of offending chemotherapeutic agent was 13.3 days. Mean time to resolution was 29.0 days. The most common implicated drug was cytarabine, followed by clofarabine (see Table 1). The most common clinical presentation was bilateral erythema, edema and pain in the palm and soles with varied intertriginous involvement. Other significant coexisting variations included dermatomyositis-like features, hyperpig-mentation, bullous and violaceous erythema with li-chenoid papules. The most common histological find-ing was vacuolar interface dermatitis and dysmatura-tion of keratinocytes. Conclusion: We conclude that rather than having an exponential number of terms to describe toxic reac-tions to cytotoxic chemotherapy agents, consolidating the clinical and histological features into a singular term as TEC. We believe this will aid in timely recognition, diagnosis and referral onto dermatology specialists for subsequent management.
Biography

Alvaro J Rodriguez, MD, is currently a Medicine Resident Physician at the Icahn School of Medicine at Mount Sinai West. He is the author of recently published textbook. “Dermatology for the USMLE”. He has dedicated a major part of his medical career to teaching and helping students prepare for the USMLE, including teaching re-view courses. His interest in dermatology includes DRESS syndrome, toxic erythema of chemotherapy, atopic dermatitis, psoriasis and infectious skin disorders.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

ph[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords